Implementation Strategies for Monitoring Adherence in Real Time (iSMART) for Oral Anticancer Therapies
Oral therapies in the treatment of lung cancer have unique side effect profiles that can lead to suboptimal adherence if not adequately managed, contributing ultimately to decreased effectiveness, increased toxicity, and higher costs. The objective of the iSMART project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effects of a bidirectional, conversational agent on adherence using a two-arm randomized controlled trial, and explore factors shaping the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from patients and clinicians.
By combining innovations from behavioral economics and machine learning with highly accessible text-messaging platforms, our project has the potential not only to identify scalable, patient-targeted strategies for improving adherence to oral therapies, but also to transform the way cancer care is delivered and implemented. Early piloting suggests that the chatbot will improve symptom monitoring and adherence to cancer therapies. These early findings will be evaluated in the ongoing randomized controlled trial with estimated 140 participants with lung cancer.
Katharine Rendle, PhD, MSW, MPH; Samuel Takvorian, MD; Justin Bekelman, MD: Lawrence Shulman, MD; Stephen Kimmel, MD, MSCE; E. Paul Wileyto, PhD; Michael Serpa, MS; Roy Rosin, MBA; Bethany Mooney, CRNP, MSN; and Christine Cambareri, BCPS, BCOP, CSP.
Abramson Cancer Center Cancer Control Program and the Departments of Medicine, Division of Hematology Oncology, Radiation Oncology, Family Medicine and Community Health, and Biostatistics, Epidemiology, and Informatics.
Lung Cancer Research Foundation-Pfizer Competitive Research Grant Program
Augmented & Artificial Intelligence
Incentives to Change Behavior